Upgrade to SI Premium - Free Trial

KalVista Pharmaceuticals (KALV)

26.99 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (9/3/26)

Latest Headlines

Form SC TO-T/A KalVista Pharmaceuticals Filed by: Chiesi Farmaceutici SpA June 1, 2026 9:06 AM - SEC Filing Form SC 14D9/A KalVista Pharmaceuticals Filed by: KalVista Pharmaceuticals, Inc. June 1, 2026 9:05 AM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 27 Filed by: Yea Christopher May 29, 2026 4:05 PM - SEC Filing KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema May 28, 2026 7:00 AM - BizWire Form 144 KalVista Pharmaceuticals Filed by: Yea Christopher May 27, 2026 5:19 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 22 Filed by: Audhya Paul K. May 27, 2026 4:06 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 22 Filed by: Sweeny Nicole May 27, 2026 4:06 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 22 Filed by: Yea Christopher May 27, 2026 4:06 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 21 Filed by: Palleiko Benjamin L May 26, 2026 7:35 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 21 Filed by: Sweeny Nicole May 26, 2026 7:35 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 21 Filed by: Yea Christopher May 26, 2026 7:34 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 21 Filed by: Audhya Paul K. May 26, 2026 7:33 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 21 Filed by: Piekos Brian May 26, 2026 7:33 PM - SEC Filing Form SCHEDULE 13D/A KalVista Pharmaceuticals Filed by: Frazier Life Sciences Public Fund, L.P. May 21, 2026 4:46 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 17 Filed by: Yea Christopher May 19, 2026 4:06 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 17 Filed by: Audhya Paul K. May 19, 2026 4:05 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 17 Filed by: Palleiko Benjamin L May 19, 2026 4:04 PM - SEC Filing Form SCHEDULE 13G/A KalVista Pharmaceuticals Filed by: Point72 Asset Management, L.P. May 15, 2026 4:32 PM - SEC Filing Form 10-Q KalVista Pharmaceuticals For: Mar 31 May 14, 2026 4:07 PM - SEC Filing Form SC 14D9 KalVista Pharmaceuticals Filed by: KalVista Pharmaceuticals, Inc. May 13, 2026 4:45 PM - SEC Filing Form SCHEDULE 13G KalVista Pharmaceuticals Filed by: SILVERARC CAPITAL MANAGEMENT, LLC May 13, 2026 4:41 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: May 11 Filed by: Palleiko Benjamin L May 13, 2026 4:25 PM - SEC Filing Form SC TO-T KalVista Pharmaceuticals Filed by: Chiesi Farmaceutici SpA May 13, 2026 7:23 AM - SEC Filing Stifel Downgrades Kalvista Pharmaceuticals Inc (KALV) to Hold on Proposed Acquisition May 7, 2026 4:43 PM - StreetInsider Form SC TO-C KalVista Pharmaceuticals Filed by: Chiesi Farmaceutici SpA May 5, 2026 4:52 PM - SEC Filing Form SCHEDULE 13G/A KalVista Pharmaceuticals Filed by: MILLENNIUM MANAGEMENT LLC May 1, 2026 5:33 PM - SEC Filing H.C. Wainwright Downgrades Kalvista Pharmaceuticals Inc (KALV) to Neutral May 1, 2026 6:05 AM - StreetInsider Form 10-KT/A KalVista Pharmaceuticals For: Dec 31 April 30, 2026 4:38 PM - SEC Filing Needham Downgrades Kalvista Pharmaceuticals Inc (KALV) to Hold April 30, 2026 1:03 PM - StreetInsider Jones Trading Downgrades Kalvista Pharmaceuticals Inc (KALV) to Hold April 30, 2026 3:29 AM - StreetInsider Form SC14D9C KalVista Pharmaceuticals Filed by: KalVista Pharmaceuticals, Inc. April 29, 2026 5:11 PM - SEC Filing Citizens Downgrades Kalvista Pharmaceuticals Inc (KALV) to Market Perform April 29, 2026 1:15 PM - StreetInsider Form 8-K KalVista Pharmaceuticals For: Apr 29 April 29, 2026 8:31 AM - SEC Filing Chiesi to acquire KalVista for $1.9 billion in rare disease expansion April 29, 2026 7:42 AM - StreetInsider Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio April 29, 2026 7:42 AM - BizWire Chiesi to acquire KalVista Pharmaceuticals for $1.9 billion April 29, 2026 7:40 AM - StreetInsider Form 4 KalVista Pharmaceuticals For: Apr 16 Filed by: Audhya Paul K. April 20, 2026 7:42 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: Apr 16 Filed by: Sweeny Nicole April 20, 2026 7:42 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: Apr 16 Filed by: Piekos Brian April 20, 2026 7:41 PM - SEC Filing Form 4 KalVista Pharmaceuticals For: Apr 16 Filed by: Palleiko Benjamin L April 20, 2026 7:40 PM - SEC Filing Alpha Cognition appoints Bethany Sensenig to board of directors April 20, 2026 5:00 PM - StreetInsider Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig April 20, 2026 5:00 PM - BizWire These are the best biotech stocks to own in 2026: BofA April 19, 2026 10:00 AM - StreetInsider Kalvista Pharmaceuticals (KALV) Reiterated at Market Outperform by Citizens on Ekterly Sales April 16, 2026 5:07 AM - StreetInsider KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference April 8, 2026 7:00 AM - BizWire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 2, 2026 4:01 PM - BizWire KalVista reports interim Phase 3 data for pediatric HAE treatment March 30, 2026 7:01 AM - StreetInsider KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference March 30, 2026 7:00 AM - BizWire Form 4 KalVista Pharmaceuticals For: Mar 25 Filed by: VHCP Co-Investment Holdings III, LLC March 27, 2026 5:50 PM - SEC Filing H.C. Wainwrigh on Kalvista Pharmaceuticals Inc (KALV): FY25 Ekterly revs show strong demand for HAE patients March 26, 2026 11:28 AM - StreetInsider Kalvista Pharmaceuticals (KALV) PT Lowered to $28 at Citizens - 'Performance in line' March 26, 2026 4:38 AM - StreetInsider Form 10-KT KalVista Pharmaceuticals For: Dec 31 March 25, 2026 4:36 PM - SEC Filing Kalvista Pharmaceuticals Inc (KALV) PT Raised to $42 at Stifel March 25, 2026 4:22 PM - StreetInsider Jefferies stays Buy on Kalvista Pharmaceuticals Inc (KALV) after FY25 results March 25, 2026 4:08 PM - StreetInsider Leerink Partners on Kalvista Pharmaceuticals Inc (KALV): 'we continue to view this as a launch investors should own' March 25, 2026 8:28 AM - StreetInsider Form 8-K KalVista Pharmaceuticals For: Mar 25 March 25, 2026 7:18 AM - SEC Filing KalVista reports $49.1 million EKTERLY revenue in eight-month period March 25, 2026 7:01 AM - StreetInsider KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update March 25, 2026 7:00 AM - BizWire KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 March 18, 2026 7:00 AM - BizWire Full Article List